Showing results (331-340 of 3,716) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|August 11, 2019
A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancerHao Luo, Liang Zhang, Bo Yang, et al.Investigational New Drugs|August 16, 2019
Identification of HGF as a novel target of miR-15a/16/195 in gastric cancerDongying Liu, Haiyang Zhang, Shaohua Ge, et al.Investigational New Drugs|March 23, 2011
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancerA B El-Khoueiry, R K Ramanathan, D Y Yang, et al.Investigational New Drugs|March 23, 2011
In vivo toxicity study of N-1-sulfonylcytosine derivatives and their mechanisms of action in cervical carcinoma cell lineJelena Kašnar-Šamprec, Ivana Ratkaj, Katarina Mišković, et al.Investigational New Drugs|February 1, 1990
Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neckD E Mattox, D D Von Hoff, S P BalcerzakInvestigational New Drugs|June 2, 2011
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinomaAndrew H Ko, Hagop Youssoufian, Jayne Gurtler, et al.Investigational New Drugs|April 22, 2011
Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death pathwaysGili Berkovitch-Luria, Michal Weitman, Abraham Nudelman, et al.Investigational New Drugs|August 1, 1990
A phase II study of menogaril (NSC-269148) in colorectal carcinoma. A Southwest Oncology Group studyR P Whitehead, R H Earhart, T Fleming, et al.Investigational New Drugs|January 1, 1990
Phase II trial of methylglyoxal bis-guanylhydrazone (MGBG) in refractory small cell lung cancerM S Simon, J Eckenrode, R B NataleInvestigational New Drugs|May 27, 2011
Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patientsOlivier Mir, Jérôme Alexandre, Romain Coriat, et al.Pageof 372